All clinical trials must have a written Data and Safety Monitoring (DSM) plan. Many clinical trials activated at the Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) are multicenter trials and have a DSM plan that has been previously approved by an appropriate authority external to VCU. Although not required by NCI CCSG guidelines or NCI/NIH policy, the MCC default DSM plan for clinical trials is a DSMB. DSMBs evaluate ongoing trials for data integrity and subject safety. DSMB recommendations are reported to investigators and the IRB. If a DSMB identifies problems so serious as to raise doubts about the meaningfulness of the results of a trial, it also reports its findings to the Protocol Review and Monitoring Committee (PRMC). Although DSMBs make recommendations, the DSMB function is an advisory function. In addition to the DSMB, a DSM plan generally contains two other components: the Study Team and an Audit Committee (AC). The Study Team is the group primarily responsible for study conduct. In most cases, the study team consists of the Investigator(s), Study Biostatistician, a Research Nurse, a Clinical Research Associate, and a Regulatory Expert. Study teams meet regularly as appropriate for an individual study. ACs audit trials for regulatory compliance, protocol compliance, and data quality. AC findings are reported to the investigator and the trial DSMB. Although the AC may make recommendations, the AC function is a fact finding function.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Virginia Commonwealth University
United States
Zip Code
Ding, Boxiao; Parmigiani, Anita; Divakaruni, Ajit S et al. (2016) Sestrin2 is induced by glucose starvation via the unfolded protein response and protects cells from non-canonical necroptotic cell death. Sci Rep 6:22538
Terracina, Krista P; Graham, Laura J; Payne, Kyle K et al. (2016) DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunol Immunother 65:1061-73
Alotaibi, Moureq; Sharma, Khushboo; Saleh, Tareq et al. (2016) Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells. Radiat Res 185:229-45
Truchan, Hilary K; Cockburn, Chelsea L; Hebert, Kathryn S et al. (2016) The Pathogen-Occupied Vacuoles of Anaplasma phagocytophilum and Anaplasma marginale Interact with the Endoplasmic Reticulum. Front Cell Infect Microbiol 6:22
Menezes, M E; Das, S K; Minn, I et al. (2016) Detecting Tumor Metastases: The Road to Therapy Starts Here. Adv Cancer Res 132:1-44
Agarwal, Stuti; Bell, Catherine M; Taylor, Shirley M et al. (2016) p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb. Mol Cancer Res 14:66-77
Lafata, Jennifer Elston; Shay, L Aubree; Brown, Richard et al. (2016) Office-Based Tools and Primary Care Visit Communication, Length, and Preventive Service Delivery. Health Serv Res 51:728-45
Gewirtz, David A (2016) The Challenge of Developing Autophagy Inhibition as a Therapeutic Strategy. Cancer Res 76:5610-5614
Ge, Xiuchun; Shi, Xiaoli; Shi, Limei et al. (2016) Involvement of NADH Oxidase in Biofilm Formation in Streptococcus sanguinis. PLoS One 11:e0151142
Korwar, Sudha; Morris, Benjamin L; Parikh, Hardik I et al. (2016) Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP). Bioorg Med Chem 24:2707-15

Showing the most recent 10 out of 413 publications